Main Article Content
Back ground: Diabetes mellitus and hyperlipidemia are the most common coexisting conditions across the world.
Hence, to treat these types of patients both antidiabetic and antihyperlipidemic combination of drugs has to be
advised. The most commonly used safe drugs metformin and fenofibrate combination has been selected for our
study. Thus, this study was performed to investigate the pharmacokinetic and pharmacodynamic interactions
between these two above mentioned drugs in animal models. Materials and Methods: Diabetes and hyperlipidemia
in rats were induced by streptozocin and cholesterol rich diet regimen and thereafter treated with metformin and
fenofibrate. The blood samples were collected to evaluate plasma drug concentrations using high-performance
liquid chromatography. Results: Single dose of metformin and fenofibrate individually and concomitantly treated
in diabetic hyperlipidemic rats. Bio-statistically no significant interactions found in pharmacokinetic parameters.
In the pharmacodynamic interaction study, the combination therapy of metformin with fenofibrate shown a
marked lipid profiles reduction when compared to fenofibrate alone treatment. Conclusion: It is proved in our
pharmacodynamic study that concurrent administration of these two drugs has potential benefit in management of
diabetes and hyperlipidemia. In addition, due to their in significant pharmacokinetic interaction, the combination
therapy will be safe and highly advantageous to the patients.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.